Celgene Bolsters Pipeline with US$9 B Purchase of Juno Therapeutics
By Jawala Prasad
Pharma Deals Review: Vol 2018 Issue 1 (Table of Contents)
Published: 30 Jan-2018
DOI: 10.3833/pdr.v2018.i1.2298 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Marketer of Revlimid® (lenalidomide), Celgene, has signed a definitive agreement to acquire Juno Therapeutics in a deal worth up to US$9 B less than three weeks after it acquired Impact Biomedicines for an upfront payment of US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS